More than 10 new drugs from The Pharmaceutical Headlines Q4 are expected to be approved involving Sanofi, Pfizer and BMS

(2020/10/27) More than 20 Chinese companies involved in more than 30 Q3 licensed transactions involving drugs have these characteristics; The chain of medical giants has accelerated its national layout; the logic behind the invalidity of the "Engle Net" core patents is clear; if bio-similar drug collections Zinda, Ziru, etc. can win... (Click on the title, get the original text) Q4 2020 Q4 more than 10 new drugs are expected to be approved for market, involving Sanofi, Pfizer, BMS well-known U.S. medical and health information website Xconomy recently published an article that said that by the end of the year, a number of new products are expected to be regulatoryly approved to enter the market, including Sanofi, Pfizer, Shishi Shiguibao's new drug projects, these drugs will be listed, will open up new business areas or shake the field of treatment.
: One of the drugs, Inmazeb, was approved by the FDA on October 15.
E drug manager: If bio-similar drug collection Zinda, Qilu ... Who can win? The Department of Health Insurance has made it clear that bio-similar drug belt purchases will be conducted in due course.
biosynthic drugs can replace the original biological drugs in China's clinical market, the main core in three aspects, one is health insurance payment, two is hospital coverage, three is doctor's prescription.
but for companies, the key to winning is price.
: With the approval of biosynthic drugs in China, the price war of bioso-like drugs is not far away.
more than 20 Chinese companies involved in more than 30 Q3 licensing transactions involving drugs have these imported products has become one of the important ways for biopharmaceutical companies to expand their product pipelines.
the third quarter of 2020, China Biopharmaceutical Company (excluding in-body diagnostics and testing) participated in at least 28 authorized transactions, according to public information.
while introducing products from outside China, such as Baiji Shenzhou, Reding Pharmaceuticals, Qilu Pharmaceuticals and Fosun Pharmaceuticals, Howson Pharmaceuticals, Tiantian Bio, etc. also licensed products to companies outside China.
addition, there have been a number of licensing transactions between Chinese biopharmaceutical companies.
: Transactions between Chinese biopharmaceutical companies continue to be active.
third quarter results of the medical profession increased significantly! The chain of medical giants accelerated the national layout on October 26, listed ophthalmology giant Eyre Ophthalmology released its third quarter 2020 report, which showed operating income of 4.402 billion yuan, up 47.55 percent year-on-year.
net profit attributable to shareholders of listed companies was RMB870 million, up 62.34% YoY, while net profit attributable to shareholders of listed companies, net of non-recurring profit and loss, was RMB1,002 million, up 85.49% YoY.
report also showed that net profit in the first three quarters was RMB1.55 billion, up 25.6% YoY.
headlines: When exactly is the market value of Eyre Ophthalmology approaching the ceiling? The logic behind the "Engele Net" core patent is completely invalid! Recently, the patent review committee of the State Information Administration decided that the compound patent of the Grigg Ingham heavy-weight variety "Engele Net" was all invalid in China, and the process was all invalidated by the application of five well-known pharmaceutical companies in China.
time, the pharmaceutical industry's long-standing case of invalid patents once again set off industry discussion, then, Engele net this product is how important? How is its core compound patent invalidated? How will domestic pharmaceutical companies benefit from this? Headline: The spears we use today will eventually evolve into a weapon for others to break our own IP!